Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

High-Premium Buyouts Continue In Hepatitis C Space; Are Idenix And Achillion Next?

Executive Summary

Bristol’s $2.5 billion tender for Inhibitex left many industry observers waiting to see what HCV players will do with only two independent pure-play HCV biotechs left. Idenix is eager to get its mid-stage nucleotide free of an FDA partial clinical hold, while Achillion says it has the assets to go it alone in the HCV competition.

You may also be interested in...



BioCryst Joins HCV Race With $101M Presidio Merger

BioCryst’s proposed merger with Presidio will give the company an instant HCV pipeline. Albeit early-stage, the variety of the drugs could give the company a strong hand against other players in the field.

Still In The Race: Achillion Says Its HCV Candidates Are “Best-In-Class”

In a year of turmoil in HCV drug development, Achillion has advanced just by staying steady. The biotech’s plans are rooted in an NS5A inhibitor that shows efficacy in patients with mutated strains of the virus and a strong-performing protease inhibitor.

Still In The Race: Achillion Says Its HCV Candidates Are “Best-In-Class”

In a year of turmoil in HCV drug development, Achillion has advanced just by staying steady. The biotech could do so with an NS5A inhibitor that shows efficacy in patients with mutated strains of the virus and a strong-performing protease inhibitor.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS054105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel